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Objective: To evaluate the effect of domperidone use on corrected QT
interval in premature infants.
Study Design: A prospective study of premature infants receiving
domperidone was included in this study. A baseline electrocardiogram was
obtained just before and 3, 7 and 14 days after initiation of domperidone.
Corrected QT was considered prolonged if it exceeded the upper limit
for age.
Result: A total of 40 premature infants were enrolled in this study. The
mean birth weight of 1109±332g, mean gestational age of 28.8±2.4
years and mean age at the onset of domperidone were 32.8±2 days. No
difference in corrected QT interval was observed between just before and 3,
7 and 14 days after the start of the treatment. Two infants had corrected
QT interval prolongation without any clinical side effect that resolved
spontaneously.
Conclusion: Our experience suggests that domperidone administered
cautiously in modest doses does not result in arrhythmias or conduction
defects in premature infants statistically. Additional data are needed to
give optimal advice regarding the safety of domperidone treatment in
premature infants.
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Introduction
Domperidone is a prokinetic agent that is commonly used for a
variety of motility disorders including gastroesophageal reﬂux and
constipation. It has been in the market worldwide since 1978.
Chemically distinct from cisapride, domperidone is a peripheral
dopamine 2-receptor antagonist. Unlike metoclopramide, another
prokinetic dopamine-receptor antagonist, domperidone does not
readily cross the blood–brain barrier and reports of adverse effects
on the central nervous system, such as dystonic reactions, are
rare.
1,2 On account of its apparent favorable safety proﬁle,
domperidone might seem to be safer as an alternative to cisapride
and metoclopramide.
However, QT interval (QT) prolongation and life-threatening
ventricular tachyarrhythmias have been reported with
domperidone.
2–6 Domperidone possesses cardiac
electrophysiological effects similar to those of cisapride and class
III antiarrhythmic drugs. These effects are observed at clinically
relevant concentrations of the drug. The experimental studies
carried out by Drolet et al.
7 showed that domperidone can prolong
cardiac repolarization in a reverse rate-dependent manner by
blocking the cardiac potassium current (IKr: rapidly activating
delayed rectiﬁer K
þ current). Excessive IKr block may lead to
triggered tachyarrhythmias and sudden death.
8 The study by Drolet
et al.
7 provided a new explanation for QT prolongation and
ventricular tachyarrhythmia during domperidone treatment.
Domperidone should be one of the next compounds to add to the
growing list of drugs associated with acquired long QT syndrome.
Therefore, domperidone should not be considered a no-risk
alternative to cisapride.
In the literature, no systematic study has been performed to
evaluate the effect of domperidone on the QT interval in premature
infants. Premature infants and neonates may be at higher risk
because of the reduced activity of the cytochrome p450 enzymes in
this age group.
7–9 These cardiac side effects should be evaluated
because the restrictions on cisapride have resulted in the overuse of
domperidone.
The aim of this study was to evaluate the effect of domperidone
use on corrected QT (QTc) interval in premature infants.
Methods
The prospective study was carried out in our neonatal unit from
January 2006 until August 2008. All infants with a gestational age
of p34 weeks admitted to the unit who decided to start
domperidone treatment were included in this study. All premature
infants who had not reached the postconceptional age of 37 weeks
at that time were eligible. Exclusion criteria for QTc interval
analysis was either increased QTc interval (X0.45) before
domperidone administration or a family history of long QT Received 21 March 2009; accepted 14 May 2009; published online 23 July 2009
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that could increase the QTc interval, for example, electrolyte
abnormalities, hypothyroidism, intracranial disorders, renal or
hepatic abnormalities and those using a macrolide antibiotic
or azole antifungal at any stage during the study. A blood
test for potassium, calcium and magnesium levels was available for
all the infants included in the survey. Congenital hypothyroidism
was excluded in all infants by dosage with thyrotrophin and thyroid
stimulating hormone on day 7, as part of the neonatal screening
procedure for premature infants. For each infant, birth weight,
gestational age, small for gestational age, postnatal age,
postconceptional age, weight on the day of the start of treatment
and associated treatments were recorded. Each infant acted as its
own control.
Domperidone was started in the dose of 0.25mgkg
 1 every
6h before feeding. The drug was always given through the
gastrointestinal tract, orally or through a nasogastric tube. They
were reweighed after 7 days and the dose was adjusted for their new
weight. A base-line electrocardiogram (ECG) was obtained just
before starting domperidone. Follow-up ECG was obtained 3, 7 and
14 days after the initiation of therapy. All infants were placed on
continuous bedside ECG monitoring, which is standard in a
neonatal intensive care unit during the entire hospitalization
period. ECG was performed with a Hewlett–Packard Page Writer
100 model (Hewlett–Packard, Bracknell, UK) M1705B, with a
paper speed of 25mms
 1 to allow a precise measure of QTc
interval. All ECG studies were evaluated by a single cardiologist
who was blinded both to the patients and the frequency of
administration of domperidone. QT interval was corrected for the
heart rate using Bazzet’s formula (QTc¼QT/OR R) in ﬁve
non-consecutive beats using lead II, and ﬁve values were then
averaged. The longest QT interval was also identiﬁed on each ECG.
Corrected QT was considered prolonged if it exceeded the upper
limit for age (QTc interval X0.45s).
10
The study protocol was approved by the hospital’s research,
scientiﬁc and ethics committee. Parents’ informed consent was
taken for all eligible infants.
Statistical analysis
Statistical analysis was performed using a standard commercial
software package (SPSS version 13.0, SPSS Inc., Chicago, IL, USA).
Descriptive analysis was presented as the mean±s.d. Comparisons
between QTc interval before and after domperidone were performed
by the analysis of variance followed by the Fisher’s least signiﬁcant
difference test. Inter-subgroup comparisons were performed by
Student’s t-test. A P-value of <0.05 was considered statistically
signiﬁcant.
Results
A total of 43 premature infants were enrolled in the study. Three
infants were excluded because of the concomitant prescription of
drugs known to increase the QTc interval. Indications for
domperidone treatment included severe gastroesophageal reﬂux
disease with feeding intolerance, apnea, bradycardia episodes and
suspected intestinal motility disorder in premature infants.
The neonates included in our study were born between 24 and
33 weeks of gestational age (mean: 28.8±2.4 weeks), weighing
between 600 and 1760g (mean: 1109±332g). On the ﬁrst day of
domperidone treatment, the mean postnatal age was 32.8±2 days.
Patient characteristics are given in Table 1.
No difference in QTc interval was observed between just before
and 3, 7 and 14 days after the start of treatment. The mean QTc
interval before and after 3 days, before and after 7 days, and before
and after 14 days of domperidone was similar (P¼0.469,
P¼0.940 and P¼0.951, respectively) (Table 2). The QTc interval
increased to above 0.45 in two infants at day 7 on domperidone
treatment. The gestational age of these infants was 26 and
30 weeks and the QTc intervals were 0.49 and 0.46s at day 7.
However, this prolongation of QTc interval was not associated with
the occurrence of rhythm disorders. QTc prolongation returned to
Table 1 Characteristics of patients treated with domperidone (n¼40)
Study group (n¼40)
Gestational age mean±s.d. (week) 28.8±2.4 (24–33)
Birth weight (g) mean±s.d. 1109±332 (600–1760)
Male n (%) 65 (67)
Small for gestational age 5 (12.5)
Age at onset of domperidone (day) 31.7±9.8
Mean postconceptional age (weeks) 32±2 (29–35)
Mean weight at onset of domperidone (g) 1392±390
Table 2 Evaluation of QTc interval before and during domperidone administration (n¼40)
QTc at baseline QTc at day 3 QTc at day 7 QTc at day 14 P-value*
Mean QTc interval (s) (s.d.) 0.37±0.03 0.38±0.03 0.37±0.04 0.37±0.03 0.877
Number with increase in QTc (n)0 0 2 0 F
Number with arrhythmia (n)0 00 0 F
Abbreviation: QTc, corrected QT interval.
*0–3 day, P¼0.469; 0–7 day, P¼0.940; 0–14 day, P¼0.951.
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during their stay in our neonatal unit, no cardiac arrhythmias or
atrioventricular conduction abnormalities by bedside ECG
monitoring were seen in any of the study infants.
Discussion
Gastroesophageal reﬂux (GER) and GER disease occur frequently
during the ﬁrst months of life. Owing to the immaturity of the
esophagus and stomach, some complications of GER occur more
frequently especially in preterm infants. In preterm infants, empiric
therapy is often administered using the agents of unproven efﬁcacy
and safety to treat symptoms that are likely unrelated to GER. In a
survey on management practices for GER in preterm infants, the
common treatment strategies included are positioning, feed
thickeners, histamine2 receptor antagonists, antacids, prokinetics,
proton pump inhibitors and dopamine receptor antagonists. The
safety, efﬁcacy and appropriate dosing recommendations for most
medical therapies remain uncertain in neonates.
11,12
There are limited studies evaluating the efﬁcacy and adverse
effects of domperidone in a neonatal population. Clinical attention
should be directed toward QT prolongation and proarrhythmic
events when domperidone is administered, as it was with cisapride,
because domperidone is a potent IKr blocker.
7 K
þ channel
expression and activity are particularly sensitive to the changes
during development.
13,14 Wang et al.
13 have found that in a
neonatal mouse heart, novel expression of the ATP regulated K
þ
channel at early and late stages of embryonic development, which
may indicate a functional role for this channel during
morphogenesis of the heart and Ikr, has a more prominent role in
the cardiac conduction system than it does in the adult mouse
heart. These results may be important to the preterm and newborn
infant in clinical practice.
These potentially signiﬁcant side effects of domperidone can
increase with the concomitant prescriptions known to increase the
QT interval. In the neonatal intensive care unit, other IKr blockers
such as class III antiarrhythmic drugs and drugs that inhibit P450
enzyme, which are important for drug clearance, can be
commonly used. In addition, the P450 system seems to be less
developed in the preterm infant, and so the risk of toxicity is
high.
9,14 Dailly et al.
15 showed that there is no clinically relevant
change in domperidone elimination in preterm neonates. However,
therapeutic concentrations can be different between adults and
preterm neonates.
Earlier reports of domperidone cardiac toxicity suggest that
domperidone may not always be safe in some small children and
that the use of concomitant medications or some conditions may
cause QTc prolongations.
7,9,16–19 In a recent study, Djeddi et al.
20
reported QT prolongation in infants treated with domperidone.
Mean QTc prolongation was 0.14s and only one infant developed a
QTc of longer than >0.45s. This study showed a signiﬁcant
association between oral domperidone and QTc prolongation in the
infants’ group with a gestational age of X32 weeks, but not in the
group with a gestational age of <32 weeks.
In our study, administering a daily dose of 0.25mgkg
 1 every
6h of domperidone treatment did not affect the QTc interval in
premature infants statistically. However, for the general population
in premature infants, these studies do not imply that there is no
risk associated with domperidone-induced increase in QTc, as two
infants in this study had QTc interval prolongation. Additional data
are needed to give optimal advice regarding the safety of
domperidone treatment in premature infants. Owing to the
insufﬁciency of clinical studies related to domperiodone in
premature infants and the potential cardiac side effects of
the drug, treatment should be chosen carefully and the patient
should be observed for QT prolongation from the beginning of the
treatment.
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